Make a Donation

Scope

The LHCE carries out investigations at the interface of basic and clinical cancer research.

Our investigations focus on the molecular mechanisms that govern cell death and the cellular resistance to chemotherapy in hematological and non-hematological cancers. We carry out fundamental research projects and are also actively involved in the identification of promising therapeutic strategies, including novel combination strategies for extending patient survival. Important cell death pathways that are the focus of current studies include apoptosis and autophagy. Other lines of research also explore the mechanisms underlying the repair of DNA damage induced by anticancer drugs, and the role of DNA repair proteins in genomic stability and chromatin integrity. Recently, studies aiming to discover cancer protein and miRNA biomarkers in blood samples have been initiated and implemented in the laboratory in order to improve early diagnostic and treatment. 

Contact

Laboratory of Experimental Hemato-Oncology
Head of Research Unit: Dr. Guy Berchem
CRP-Santé, BAM
84, Val Fleuri, L-1526 Luxembourg
Tel: (+352) 44 11 20 84
Secretary: audrey.lemasson@crp-sante.lu
Phone: (+352) 26 970 320
Fax: (+352) 44 12 15
E-mail: berchem.guy@chl.lu

Find on Google Map

Make a Donation

ACTIVITIES

Within the Department of Oncology, the Laboratory of Experimental Hemato-Oncology (Laboratoire d’Hemato-Cancérologie Expérimentale, LHCE) is distinguished as one of the first basic cancer research laboratories in Luxembourg.

As part of a large network of national and international collaborations initiated by LHCE, the laboratory has become a major partner in the initiatives to accelerate bio-medical research launched by the Government of Luxembourg in collaboration with several US institutions.
Generous donations and competitive funding from governmental and non-governmental organizations has enabled LHCE to carry out cutting-edge research at the interface of basic and clinical cancer research.  

Research within LHCE is focused on 2 major areas:

1) the molecular mechanisms that govern cell death and,

2) the cellular resistance to chemotherapy in hematological and non-hematological cancers.
Research interests also include identification of novel therapeutic strategies, improvement of early cancer diagnosis, and the exploration of the mechanisms underlying the repair of DNA damage induced by anticancer drugs.

Flow-cytometry core facility

The LHCE has set up a flow-cytometry core facility  which is now routinely used for immunophenotyping of cells using specific markers and for the investigation a various cell phenomena (e.g., apoptosis, ROS generation).
 
The LHCE also benefits from to in house collaborations and access to the various facilities and platforms of the CRP-Santé, including the Microarray Center, the newly-created Proteomic Unit, the Integrated Biobank of Luxembourg (IBBL), confocal microscopy, and laser dissection microscopy.

Major activities